Skip to main
HRMY

HRMY Stock Forecast & Price Target

HRMY Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Harmony Biosciences Holdings Inc. is projected to experience significant growth in WAKIX sales, with expectations to rise from approximately $160 million in 2020 to over $700 million by 2024, driven by the drug's safety and convenience advantages. The company’s promising pipeline includes multiple drug candidates, such as pitolisant in Phase 2 trials and the development of pitolisant-GR, which aims to enhance patient adherence by eliminating the need for dose titration. With a strong balance sheet to support both research and development and upcoming clinical trials, Harmony is positioned as a compelling growth story in the neurology sector.

Bears say

Harmony Biosciences Holdings Inc faces a negative outlook primarily due to the failure of its pivotal Phase 3 RECONNECT trial for ZYN002, which did not meet the primary endpoint, raising concerns about the effectiveness of the drug in treating Fragile X syndrome. Additionally, the company may encounter increased competition in the sodium oxybate market, which could hinder the growth of its leading product, Wakix, while a slowdown in new patient additions could further exacerbate this issue. Furthermore, uncertainties surrounding the success of ongoing clinical trials for various other candidates in its pipeline contribute to a bleak financial outlook for Harmony.

HRMY has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Harmony Biosciences Holdings (HRMY) Forecast

Analysts have given HRMY a Strong Buy based on their latest research and market trends.

According to 7 analysts, HRMY has a Strong Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Harmony Biosciences Holdings (HRMY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.